Bristol Myers Squibb (BMY) Invested Capital (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Invested Capital for 18 consecutive years, with $66.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital fell 6.95% year-over-year to $66.2 billion in Q2 2026; TTM through Jun 2026 was $66.2 billion, a 6.95% decrease from a year earlier, with the FY2025 full-year figure at $65.6 billion, down 3.35% from the prior year.
• Invested Capital was $66.2 billion for Q2 2026 at Bristol Myers Squibb, down from $66.6 billion in the prior quarter.
• Over five years, Invested Capital peaked at $83.9 billion in Q1 2022 and troughed at $65.6 billion in Q4 2025.
• A 5-year average of $71.9 billion and a median of $71.9 billion in 2023 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital declined 15.05% in 2022 and advanced 5.9% in 2025, its largest moves.
• Over 5 years, Invested Capital stood at $74.3 billion in 2022, then decreased by 2.97% to $72.1 billion in 2023, then retreated by 5.91% to $67.9 billion in 2024, then decreased by 3.35% to $65.6 billion in 2025, then advanced by 0.93% to $66.2 billion in 2026.
• The last three Invested Capital figures came in at $66.2 billion (Q2 2026), $66.6 billion (Q1 2026), and $65.6 billion (Q4 2025), per Business Quant data.